After a year of countless exits in the ecosystem, many among the most significant yet – so much so that five nominees were not enough to recognise them all – the Award for Exit of the Year was one of the most difficult to determine.

Winner of the CVC Investment in a Spinout of the Year: Ribon Therapeutics - Novartis Venture Fund, Johnson & Johnson Innovation–JJDC, Takeda Ventures, Celgene

Of the strong candidates for GUV’s Deal of the Year, Lund and Edinburgh universities-founded drug developer Galecto Biotech sealed the award for a €79m ($90m) series C close that supplemented a promising set of clinical data for its lead candidate.

William Taranto spoke about his near decade at Merck Global Health Innovation Fund and how corporate venturing has evolved in that time.

Medtronic, LivaNova and Baxter Healthcare have helped commit $53.5m for the third medical device-based fund to be raised under the MD Start moniker.

Alphabet, Novartis and Johnson & Johnson have contributed to a series C round for Cala Health, which is preparing to release its wearable hand-tremor treatment device.

Susquehanna International Group has led a series B round for elderly healthcare services provider Shanzhen that was in the eight-figure dollar range.

Members of science incubator Unit DX have obtained $25.5m of capital altogether since launch in 2017, with many of its residents hailing from University of Bristol.

The drug development software provider has added $25m to an Alphabet and Wuxi AppTech-backed first tranche it closed in January.

Lundbeckfond Ventures contributed to a round that will fund clinical trials for Reneo Pharmaceuticals' mitochondrial disease therapies.